Evidence map›Paper›PMID 42238245›Full record

Trial reportFrontiers in endocrinology2026

Efficacy of 12-week treatment with polyethylene glycol loxenatide in obesity or overweight patients with type 2 diabetes: a multicenter, prospective cohort study based on the flash glucose monitoring system.

Liye Zhu, Hongning Li, Yuyang Zhang, Shanshan Tao, Rengna Yan, Yong Luo, Ziyang Shen, Huiqin Li, Xiaocen Kong, Jianhua Ma

Registry-linked trialAbstract readMulticenter StudyClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05611684 (Nanjing First Hospital, Nanjing Medical University), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05611684 phase4unknown statusnot on this map

Nanjing First Hospital, Nanjing Medical University

TypeinterventionalSponsorNanjing First Hospital, Nanjing Medical UniversityRan2022 to 2025Enrolled480ConditionsType2 Diabetes MellitusArmsPolyethylene Glycol Losenatide
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Liye Zhu *Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Hongning Li *Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yuyang Zhang *Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Shanshan TaoDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Rengna YanDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yong LuoDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ziyang ShenDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Huiqin LiDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaocen KongDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jianhua MaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To investigate the factors influencing the glucose-lowering efficacy of polyethylene glycol loxenatide (PEG-Loxe) added to diet, exercise, and existing glucose-lowering therapies in patients with poorly controlled type 2 diabetes mellitus (T2DM) after 12 weeks of treatment. Methods: This multicenter prospective cohort study with a pre-post intervention design, based on the FreeStyle Libre flash glucose monitoring (FGM) system, enrolled T2DM patients with inadequate glycemic control (HbA Results: Of the 500 initially enrolled patients, 246 patients were included in the final analysis. Baseline HbA Conclusions: PEG-Loxe significantly improved glycemic control in Chinese patients with T2DM who were overweight or obese. Patients who were younger, had a shorter duration of diabetes, and presented with higher baseline glucose levels appeared to derive greater benefit from the therapy. Beyond glycemic control, PEG-Loxe might also show additional benefits across multiple cardiometabolic indices. Clinical trial registration: www.clinicaltrials.gov, identifier NCT05611684.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsObesityOverweightPolyethylene GlycolsAgedBlood GlucoseBlood Glucose Self-MonitoringContinuous Glucose MonitoringFemaleGlycated HemoglobinHumansMaleMiddle AgedProspective StudiesTreatment OutcomeBlood GlucoseGlycated HemoglobinHypoglycemic AgentsPolyethylene Glycolsflash glucose monitoringpolyethylene glycol loxenatidepredictors of responsetime in rangetype 2 diabetes

Identifiers

PMID42238245
PMCPMC13226117

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.